Clinical Trial Update: Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Apatinib Mesylate in Differentiated Thyroid Carcinoma; no results are reported yet and the trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma

Drugs mentioned

• Apatinib Mesylate (apatinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Differentiated Thyroid Carcinoma | Phase 2 | Status: UNKNOWN